PMHS · XBRL financial data
Polomar Health Services financial statements, every quarter
The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (PMHS's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | †Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 17* | 14 | 14 | 10 | 21* | 5 | 5 | 6 | year only | 1,006 | 1,529 |
| Cost of revenue | 2 | 2* | 11 | 4 | 1 | 12* | 1 | 2 | 2 | year only | 455 | 593 |
| Gross profit | 20 | 15* | 3 | 10 | 9 | 9* | 3 | 4 | 4 | — | 550 | 936 |
| General and administrative | 71 | 18* | 69 | 20 | 256 | 702* | 399 | 557 | 619 | 9,355* | 246 | 261 |
| Total operating expenses | 71 | 18* | 69 | 20 | 268 | 698* | 419 | 567 | 633 | 9,391* | 557 | 718 |
| Operating income (loss) | (71) | (18)* | (69) | (20) | (259) | (689)* | (415) | (563) | (629) | (8,943)* | (7) | 218 |
| Interest expense | 37 | (37)* | — | — | 12 | 30* | 41 | 42 | 21 | 46* | 18 | 18 |
| Net income (loss) | (108) | (128) | (69) | (20) | (271) | (719) | (457) | (606) | (650) | (8,989) | (25) | 200 |
| Earnings per share, basic USD per share | (0.01) | — | (0.00) | 0.00 | (0.01) | — | (0.02) | (0.02) | (0.02) | — | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | (0.01) | — | (0.00) | 0.00 | (0.01) | — | (0.02) | (0.02) | (0.02) | — | 0.00 | 0.00 |
| Weighted average shares, basic thousands of shares | 108,166 | — | 109,138 | 109,138 | 27,656 | — | 27,658 | 27,667 | 28,008 | 27,718* | 28,023 | 28,056 |
| Weighted average shares, diluted thousands of shares | — | — | — | — | — | — | — | 27,665 | — | — | — | 28,056 |
- † Share count changed about 1/4 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (PMHS's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | †Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 15 | 0 | 0 | 0 | 16 | 6 | 129 | 5 | 39 | 132 | 88 | 179 |
| Inventory | — | 3 | — | — | 140 | 69 | 70 | 74 | 159 | 94 | 209 | 99 |
| Total current assets | 129 | 0 | 0 | 0 | 156 | 77 | 201 | 93 | 198 | 323 | 468 | 781 |
| Property and equipment, net | — | — | — | — | 88 | 81 | 72 | 62 | 53 | 43 | 34 | 24 |
| Right-of-use asset | — | 82 | — | — | 57 | 49 | 41 | 32 | 24 | 15 | 6 | — |
| Goodwill | — | — | — | — | 250 | — | — | — | — | — | — | — |
| Total assets | 129 | 0 | 0 | 0 | 10,295 | 9,952 | 9,809 | 9,433 | 9,270 | 390 | 517 | 815 |
| Total current liabilities | 15 | 14 | 83 | 103 | 954 | 1,338 | 1,660 | 1,037 | 1,503 | 1,612 | 1,762 | — |
| Lease liability, non-current | — | 49 | — | — | 24 | 15 | 6 | — | — | — | — | — |
| Total liabilities | 15 | 14 | 83 | 103 | 977 | 1,353 | 1,666 | 1,037 | 1,503 | 1,612 | 1,762 | 1,871 |
| Accumulated deficit | (1,271) | (1,398) | (1,467) | (1,487) | (2,192) | (2,911) | (3,368) | (3,974) | (4,623) | (13,612) | (13,638) | (13,526) |
| Total stockholders' equity | 114 | (14) | (83) | (103) | 9,318 | 8,599 | 8,142 | 8,396 | 7,767 | (1,222) | (1,246) | (1,056) |
| Total liabilities and equity | 129 | 0 | 0 | 0 | 10,295 | 9,952 | 9,809 | 9,433 | 9,270 | 390 | 517 | 815 |
| Common shares outstanding (cover page) thousands of shares | 109,138 | 109,138 | 109,138 | 109,138 | 27,656 | 26,658 | 27,658 | 27,945 | 28,053 | 28,053 | 28,053 | 28,381 |
- † Share count changed about 1/4 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (PMHS's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | †Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (108) | (128) | (69) | (20) | (271) | (719) | (457) | (606) | (650) | (8,989) | (25) | 200 |
| Stock-based compensation | — | — | — | — | — | — | — | — | 20* | (0)* | — | — |
| Net cash from operating activities | (117)* | (10)* | (165) | 85* | (625)* | (315)* | (46) | (188)* | (353)* | 190* | 34 | 121* |
| Purchases of property and equipment | — | — | 41 | 39* | 11* | 0* | — | — | — | — | — | — |
| Net cash from investing activities | — | — | (41) | (39)* | (11)* | 0* | — | — | — | — | — | — |
| Proceeds from issuing common stock | 106* | 0* | — | — | — | — | — | — | — | — | — | — |
| Net cash from financing activities | 104* | (5)* | 225 | (145)* | 723* | 305* | 169 | 63* | 387* | (97)* | (79) | (30)* |
| Net change in cash | (13)* | (15)* | 19 | (19)* | 7* | (10)* | 123 | (125)* | 34* | 93* | (44) | 91* |
- † Share count changed about 1/4 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| Jaguar Health | 3,788 | 1,225 | (5,338)* | not reported | 0.7 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
| Theriva Biologics | 11,337 | 0* | (3,085)* | 45.9M | 3.7 quarters | 10-QJun 30, 2026 |
| Inhibitor Therapeutics | 516 | not reported | (775)* | 173.8M | 0.7 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.